Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital stays at 'buy' on Hostelworld

(Sharecast News) - Shore Capital reiterated its 'buy' rating and 142.0p target price on Hostelworld on Thursday following the group's H1 trading update. Shore Capital noted that net revenue of €46.7m was flat year-on-year, with net bookings also flat at 3.7m, reflecting previously flagged headwinds of geographic mix, USD weakness and softness in European bed pricing, and compares with full year assumptions of "mid-single digit" revenue growth.

The broker stated that encouragingly, trading in June was said to have strengthened with both volume and ABV growth across all regions, including strong demand for intra-European travel.

"We are encouraged by commentary on strategic initiatives, notably the rollout of Elevate, its new marketplace monitisation tool, with H1 commission rates up 60bps to 15.8% in H1, despite only being launched in June," said the analysts.

Furthermore, Shore Capital noted that mobile app bookings grew 11% in H1 and the global marketplace for Trip Plans was also said to be gaining traction, helping to increase the proportion of booking from social members, rising a further 5% from last H1 to 85%.

"We believe that all this bodes well for the second half, with full year assumptions implying high-single digit net revenue growth in H2, and over the medium term," said Shore Capital.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.